Journal article
Potential of the quadrivalent human papillomavirus vaccine in the prevention and treatment of cervical cancer
SM Garland, DR Brown
Expert Opinion on Biological Therapy | TAYLOR & FRANCIS LTD | Published : 2014
Abstract
Introduction: Genital human papillomaviruses (HPVs) are readily transmissible and commonly acquired after sexual debut. With HPV being uncultivatable, it has taken the application of molecular biology to describe the virus' natural history, although it has also given us sensitive diagnostic tools, as well as underpinning the development of prophylactic viral-like particle (VLP) vaccines. Molecular epidemiology proved oncogenic HPVs as causing 100% of cervical, plus a proportion of, anogenital and oropharyngeal cancers. The quadrivalent vaccine containing VLPs 6, 11 (cause > 90% of genital warts), 16, 18, (causing 70% of cervical cancers) has shown in Phase III trials excellent safety, high e..
View full abstractGrants
Funding Acknowledgements
I, Professor SM Garland, have received advisory board fees and grant support from CSL and GlaxoSmithKline, and lecture fees from Merck, GSK and Sanofi Pasteur; in addition, I have received funding through my institution to conduct HPV vaccine studies for MSD and GSK. I am a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV.